Cited by

• Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

  Henter ID, de Sousa RT, Gold PW, Brunoni AR, Zarate CA Jr, Machado-Vieira R. Henter ID, et al. Expert Rev Clin Pharmacol. 2017 Feb;10(2):153-166. doi: 10.1080/17512433.2017.1253472. Epub 2017 Jan 16. Expert Rev Clin Pharmacol. 2017. PMID: 27781556 Free PMC article. Review.
• Identifying rare variants for genetic risk through a combined pedigree and phenotype approach: application to suicide and asthma.

  Darlington TM, Pimentel R, Smith K, Bakian AV, Jerominski L, Cardon J, Camp NJ, Callor WB, Grey T, Singleton M, Yandell M, Renshaw PF, Yurgelun-Todd DA, Gray D, Coon H. Darlington TM, et al. Transl Psychiatry. 2014 Oct 21;4(10):e471. doi: 10.1038/tp.2014.111. Transl Psychiatry. 2014. PMID: 25335167 Free PMC article.
• Use of ketamine in acute cases of suicidality.

  Lee J, Narang P, Enja M, Lippmann S. Lee J, et al. Innov Clin Neurosci. 2015 Jan-Feb;12(1-2):29-31. Innov Clin Neurosci. 2015. PMID: 25852977 Free PMC article.
• Less NMDA Receptor Binding in Dorsolateral Prefrontal Cortex and Anterior Cingulate Cortex Associated With Reported Early-Life Adversity but Not Suicide.

  Underwood MD, Bakalian MJ, Johnson VL, Kassir SA, Ellis SP, Mann JJ, Arango V. Underwood MD, et al. Int J Neuropsychopharmacol. 2020 May 27;23(5):311-318. doi: 10.1093/ijnp/pyaa009. Int J Neuropsychopharmacol. 2020. PMID: 32060512 Free PMC article.
• Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series.

  Al Shirawi MI, Kennedy SH, Ho KT, Byrne R, Downar J. Al Shirawi MI, et al. J Clin Psychopharmacol. 2017 Aug;37(4):464-467. doi: 10.1097/JCP.0000000000000717. J Clin Psychopharmacol. 2017. PMID: 28514237 Free PMC article.